Triazole-Resistant Aspergillus fumigatus in an Israeli Patient with Chronic Cavitary Pulmonary Aspergillosis Due to a Novel E306K Substitution in Hmg1

Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0108921. doi: 10.1128/AAC.01089-21. Epub 2021 Jul 19.

Abstract

Triazole resistance in the pathogenic mold Aspergillus fumigatus has increased worldwide, posing a growing therapeutic challenge. Recently, mutations in the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase gene (hmg1) have been associated with triazole resistance. Here, we describe a novel E306K triazole resistance-conferring mutation in the HMG-CoA reductase gene from an Israeli patient with chronic cavitary pulmonary aspergillosis (CCPA).

Keywords: Aspergillus fumigatus; E306K substitution; HMG1 mutations; Hmg1 resistance mutation; antifungal resistance; azole resistance; mycology; triazole resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / pharmacology
  • Antifungal Agents / therapeutic use
  • Aspergillus fumigatus / genetics
  • Drug Resistance, Fungal / genetics
  • Fungal Proteins / genetics
  • HMGB1 Protein*
  • Humans
  • Pulmonary Aspergillosis* / drug therapy
  • Triazoles / pharmacology

Substances

  • Antifungal Agents
  • Fungal Proteins
  • HMGB1 Protein
  • Triazoles